EA201892716A1 - Антитела к фактору свертывания xi - Google Patents

Антитела к фактору свертывания xi

Info

Publication number
EA201892716A1
EA201892716A1 EA201892716A EA201892716A EA201892716A1 EA 201892716 A1 EA201892716 A1 EA 201892716A1 EA 201892716 A EA201892716 A EA 201892716A EA 201892716 A EA201892716 A EA 201892716A EA 201892716 A1 EA201892716 A1 EA 201892716A1
Authority
EA
Eurasian Patent Office
Prior art keywords
coagulation factor
antibody
activation
fxia
apple
Prior art date
Application number
EA201892716A
Other languages
English (en)
Inventor
Чжу Чэнь
Кеннет П. Эллсворт
Джеймс Миллиган
Элизабет Олдхэм
Дитмар Сейфферт
Вайшнави Ганти
Мохаммад Табризифард
Бьянка Принц
Original Assignee
Мерк Шарп И Доум Корп.
АДИМАБ, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Шарп И Доум Корп., АДИМАБ, ЭлЭлСи filed Critical Мерк Шарп И Доум Корп.
Publication of EA201892716A1 publication Critical patent/EA201892716A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)

Abstract

Описаны антитела, которые связываются с доменом apple 3 человеческого фактора свертывания XI и ингибируют активацию FXI фактором свертывания XIIa, а также активацию FIX посредством FXIa.
EA201892716A 2016-06-14 2017-06-12 Антитела к фактору свертывания xi EA201892716A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662349888P 2016-06-14 2016-06-14
PCT/US2017/036940 WO2017218371A1 (en) 2016-06-14 2017-06-12 Anti-coagulation factor xi antibodies

Publications (1)

Publication Number Publication Date
EA201892716A1 true EA201892716A1 (ru) 2019-05-31

Family

ID=59078269

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892716A EA201892716A1 (ru) 2016-06-14 2017-06-12 Антитела к фактору свертывания xi

Country Status (28)

Country Link
US (6) US10676536B2 (ru)
EP (1) EP3469002A1 (ru)
JP (2) JP7022081B2 (ru)
KR (2) KR102379580B1 (ru)
CN (2) CN116425879A (ru)
AR (1) AR108717A1 (ru)
AU (3) AU2017286432B2 (ru)
BR (1) BR112018075858A2 (ru)
CA (2) CA3025869A1 (ru)
CL (1) CL2018003565A1 (ru)
CO (1) CO2018013434A2 (ru)
CR (1) CR20180583A (ru)
DO (1) DOP2018000284A (ru)
EA (1) EA201892716A1 (ru)
EC (1) ECSP18091593A (ru)
GE (1) GEP20227382B (ru)
IL (1) IL263272A (ru)
JO (1) JOP20180121A1 (ru)
MA (1) MA45234A (ru)
MX (1) MX2018015757A (ru)
MY (1) MY201852A (ru)
NI (1) NI201800134A (ru)
PE (1) PE20190416A1 (ru)
PH (1) PH12018502586A1 (ru)
SG (2) SG10202103120UA (ru)
TN (1) TN2018000417A1 (ru)
TW (2) TWI802193B (ru)
WO (1) WO2017218371A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
CN116425879A (zh) * 2016-06-14 2023-07-14 默沙东有限责任公司 抗-凝血因子xi抗体
CN110325550B (zh) 2016-12-23 2024-03-08 诺华股份有限公司 因子xi抗体和使用方法
CN110423278B (zh) * 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用
CA3184718A1 (en) * 2020-07-02 2022-01-06 Lei Wang Anti-fxi/fxia antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
EP4177275A1 (en) * 2020-07-03 2023-05-10 Suzhou Alphamab Co., Ltd Coagulation factor xi (fxi) binding protein
CN117480182A (zh) * 2021-02-09 2024-01-30 艾瑞克斯疗法有限公司 抗s100a4人源化抗体、用途和方法
CN116199782A (zh) * 2021-11-30 2023-06-02 苏州康宁杰瑞生物科技有限公司 预防和/或治疗血栓栓塞性疾病的方法

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
DE68919361T2 (de) 1988-06-21 1995-05-24 Genentech Inc Therapeutische zusammensetzungen für die behandlung von myocard-infarkten.
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
JPH0656382A (ja) 1992-08-04 1994-03-01 Kawasaki Steel Corp コークス乾式消火装置のバケット巻上機の吊ビーム装置
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
EP1135415B1 (en) 1998-12-01 2010-08-11 Facet Biotech Corporation Humanized antibodies to gamma-interferon
AU778392B2 (en) 2000-03-03 2004-12-02 Cambridge Antibody Technology Limited Human antibodies against eotaxin and their use
CA2492671C (en) 2002-03-22 2012-04-17 Aprogen, Inc. Humanized antibody and process for preparing same
ME02785B (me) 2003-07-15 2012-12-31 Amgen Inc Humana anti-ngf neutrališuća antitela kao selektivni inhibitori ngf signalnog puta
CN101120087A (zh) 2004-12-21 2008-02-06 森托科尔公司 抗-il-12抗体、表位、组合物、方法和用途
US8318906B2 (en) 2005-04-15 2012-11-27 The Regents Of The University Of California EMP2 antibodies and their therapeutic uses
SI2439273T1 (sl) 2005-05-09 2019-05-31 Ono Pharmaceutical Co., Ltd. Človeška monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka z uporabo protiteles proti PD-1 samostojno ali v kombinaciji z ostalimi imunoterapevtiki
CN101248089A (zh) 2005-07-01 2008-08-20 米德列斯公司 抗程序性死亡配体1（pd-l1）的人单克隆抗体
WO2007067992A2 (en) 2005-12-08 2007-06-14 Medarex, Inc. Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
WO2007067730A2 (en) 2005-12-08 2007-06-14 Medarex, Inc. Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use
EP2024394B1 (en) 2006-06-06 2014-11-05 Crucell Holland B.V. Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof
CA2658612C (en) * 2006-08-03 2015-11-17 Astrazeneca Ab Antibodies directed to .alpha.v.beta.6 and uses thereof
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
EP2134749B1 (en) 2007-03-22 2013-11-06 The Regents of the University of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
GB0708585D0 (en) 2007-05-03 2007-06-13 Queen Mary & Westfield College Novel antibody and use in diagnosis and therapy of arthropathies
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP3753947A1 (en) 2007-09-14 2020-12-23 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
CA2700723A1 (en) 2007-09-26 2009-04-02 Amgen Inc. Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
SI3002298T1 (sl) 2007-11-21 2019-12-31 Oregon Health & Science University Monoklonska protitelesa proti faktorju XI in postopki njihove uporabe
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
ES2702365T3 (es) * 2008-06-19 2019-02-28 Prothix Bv Uso de anticuerpos antifactor XI para la prevención o el tratamiento de la formación de trombos
CA2732003A1 (en) 2008-07-31 2010-02-04 James D. Marks Antibodies that neutralize botulinum neurotoxins
HUE031756T2 (en) 2008-10-31 2017-07-28 Janssen Biotech Inc TLR3 antagonists
CA2742968C (en) * 2008-11-07 2020-06-09 Fabrus Llc Combinatorial antibody libraries and uses thereof
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
LT2373691T (lt) * 2008-12-18 2019-05-27 Oregon Health & Science University Anti-fxi antikūnai ir jų panaudojimo būdai
CA2748158A1 (en) * 2008-12-23 2010-07-01 Astrazeneca Ab Targeted binding agents directed to .alpha.5.beta.1 and uses thereof
MX347295B (es) 2009-03-20 2017-04-20 Amgen Inc Inmunoglobulinas portadoras y usos de las mismas.
KR20110138412A (ko) 2009-04-16 2011-12-27 애보트 바이오테라퓨틱스 코포레이션 항-ΤΝＦ-α 항체 및 그의 용도
EP2426148B1 (en) 2009-04-27 2015-08-05 Kyowa Hakko Kirin Co., Ltd. Anti-il-3ra antibody for use in treatment of blood tumor
BR112012008665A2 (pt) 2009-10-12 2016-11-22 Pfizer tratamento de câncer
WO2011056997A1 (en) * 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
EP2516624B1 (en) 2009-12-23 2020-02-05 Merck Sharp & Dohme Corp. Cell line 3m
AU2011212997A1 (en) * 2010-02-03 2012-08-16 Trilogy Ip Holdings, Inc. Mobile communication plan offerings
MX360336B (es) 2010-07-16 2018-10-30 Adimab Llc Star Colecciones de anticuerpos.
JP2013540694A (ja) * 2010-08-06 2013-11-07 ウー３・フアルマ・ゲー・エム・ベー・ハー Ｈｅｒ３結合剤の前立腺治療における使用
PE20180249A1 (es) 2010-11-19 2018-02-02 Eisai Randd Man Co Ltd Anticuerpos neutralizadores anti-ccl20
JP2014506257A (ja) 2011-01-06 2014-03-13 ダイアックス コーポレーション 血漿カリクレイン結合タンパク質
ES2785081T3 (es) 2011-04-01 2020-10-05 Memorial Sloan Kettering Cancer Center Anticuerpos biespecíficos similares a receptores de células T específicos para un péptido de WT1 presentado por HLA-A2
CN103596982B (zh) 2011-06-06 2016-11-02 诺沃—诺迪斯克有限公司 治疗性抗体
US8765385B2 (en) 2011-10-27 2014-07-01 Ravindra Kumar Method of detection of neutralizing anti-actriib antibodies
PL2650310T3 (pl) 2012-04-13 2017-01-31 Rottapharm Biotech S.R.L. Przeciwciało przeciw-ADAMTS-5, jego pochodne i zastosowania
HUE040580T2 (hu) 2012-05-10 2019-03-28 Bayer Pharma AG XI. véralvadási faktorhoz és/vagy XIA aktivált alakjához kötõdni képes ellenanyagok és alkalmazásuk
JP6441792B2 (ja) 2012-05-17 2018-12-19 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｅｇｆｒに結合する抗原結合蛋白質
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
CN106232625B (zh) * 2013-10-01 2020-04-24 免疫医疗有限公司 治疗和诊断过表达α-V-β-6的癌症的方法
BR112016021576A2 (pt) 2014-03-20 2017-10-10 Japan As Represented By Director General Of Nat Institute Of Infectious Diseases ?anticorpo da proteína e2 de vírus anti-hepatite c ou fragmento do anticorpo que se liga ao antígeno da mesma, ácido nucleico, e, medicamento?
CN106456763B (zh) 2014-06-03 2018-03-13 埃克斯生物科技公司 用于治疗和预防金黄色葡萄球菌感染的组合物和方法
US20170240631A1 (en) 2014-08-08 2017-08-24 Alector Llc Anti-trem2 antibodies and methods of use thereof
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
CA2981851A1 (en) 2015-04-07 2016-10-13 Alector Llc Anti-sortilin antibodies and methods of use thereof
WO2016201389A2 (en) 2015-06-12 2016-12-15 Alector Llc Anti-cd33 antibodies and methods of use thereof
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
US11066481B2 (en) 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
EP3356415B1 (en) 2015-09-29 2024-05-01 Amgen Inc. Asgr inhibitors for reduzing cholesterol levels
KR20180104036A (ko) 2016-01-22 2018-09-19 머크 샤프 앤드 돔 코포레이션 항-응고 인자 xi 항체
CN116425879A (zh) * 2016-06-14 2023-07-14 默沙东有限责任公司 抗-凝血因子xi抗体
AU2017329645A1 (en) 2016-09-20 2019-04-04 Aronora Inc. Novel antibodies against factor XI and uses thereof

Also Published As

Publication number Publication date
AU2017286432B2 (en) 2020-09-24
GEP20227382B (en) 2022-05-25
CL2018003565A1 (es) 2019-03-22
JP7022081B2 (ja) 2022-02-17
AR108717A1 (es) 2018-09-19
US11479615B2 (en) 2022-10-25
PH12018502586A1 (en) 2019-10-07
AU2020210233B2 (en) 2024-03-07
EP3469002A1 (en) 2019-04-17
US20200255542A1 (en) 2020-08-13
US11661460B2 (en) 2023-05-30
CR20180583A (es) 2019-07-02
KR102379580B1 (ko) 2022-03-29
CA3172367A1 (en) 2017-12-21
TW201802120A (zh) 2018-01-16
CN109476758A (zh) 2019-03-15
US20200308302A1 (en) 2020-10-01
MA45234A (fr) 2019-04-17
MY201852A (en) 2024-03-20
TWI802193B (zh) 2023-05-11
MX2018015757A (es) 2019-05-30
NI201800134A (es) 2019-03-05
AU2024201084A1 (en) 2024-03-14
CN109476758B (zh) 2023-05-23
KR102218714B1 (ko) 2021-02-24
AU2020210233A1 (en) 2020-08-20
KR20190018504A (ko) 2019-02-22
TN2018000417A1 (en) 2020-06-15
US10676536B2 (en) 2020-06-09
US20230287141A1 (en) 2023-09-14
SG10202103120UA (en) 2021-05-28
JP2019521978A (ja) 2019-08-08
JP2021101720A (ja) 2021-07-15
KR20210021124A (ko) 2021-02-24
BR112018075858A2 (pt) 2019-04-02
IL263272A (en) 2018-12-31
SG11201810763TA (en) 2018-12-28
CN116425879A (zh) 2023-07-14
JP7277500B2 (ja) 2023-05-19
ECSP18091593A (es) 2019-01-31
CA3025869A1 (en) 2017-12-21
TW202214702A (zh) 2022-04-16
PE20190416A1 (es) 2019-03-19
US11512142B2 (en) 2022-11-29
TWI752964B (zh) 2022-01-21
AU2017286432A1 (en) 2018-12-06
JOP20180121A1 (ar) 2018-12-12
CO2018013434A2 (es) 2018-12-28
US20200270364A1 (en) 2020-08-27
WO2017218371A1 (en) 2017-12-21
US20200317811A1 (en) 2020-10-08
US11485794B2 (en) 2022-11-01
US20170355780A1 (en) 2017-12-14
DOP2018000284A (es) 2019-01-31

Similar Documents

Publication Publication Date Title
EA201892716A1 (ru) Антитела к фактору свертывания xi
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
EA202090104A1 (ru) Молекулы антител к cd73 и пути их применения
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
EA201892362A1 (ru) Агонистические антитела, которые связываются с cd40 человека, и варианты их применения
EA201792589A1 (ru) Антитела против cd123 и конъюгаты указанных антител
JOP20170013B1 (ar) أجسام xi مضادة لعامل مضاد للتجلط
EA201791485A1 (ru) Анти-cd47-антитела и их применения
EA201790413A1 (ru) Антитела против tigit
EA201892417A1 (ru) Антитела, распознающие тау
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
EA201692394A1 (ru) Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
EA202190609A1 (ru) Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
EA201691541A1 (ru) Новые анти-baff антитела
EA201591974A1 (ru) Антитела человека, связывающиеся с g-белком rsv
EA201600473A1 (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К Tau(PS422) И СПОСОБЫ ПРИМЕНЕНИЯ
EA201892412A1 (ru) Антитела, распознающие тау
EA202091130A1 (ru) Лиофилизованный препарат моноклонального антитела к транстиретину
EA202092849A1 (ru) Моноспецифические и мультиспецифические антитела к tmeff2 и их применение
EA201890739A1 (ru) Анти-s100a8 для лечения лейкемии
EA201890347A1 (ru) Антитела и исследования для обнаружения cd37
EA201891529A1 (ru) Композиции и способы обнаружения и лечения рака яичников
EA201891851A1 (ru) Антитела против bcma и их применение для лечения злокачественных новообразований и иммунологических нарушений